ArticleIDCases2026
Rate-controlled intravenous voriconazole rapid desensitization in a patient with chronic pulmonary aspergillosis and triazole hypersensitivity.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral triazoles, particularly itraconazole and voriconazole (VRCZ), are key antifungal agents for chronic pulmonary aspergillosis (CPA); however, hypersensitivity reactions to triazole antifungals can limit their use. We describe a 74-year-old man with CPA who developed immediate-type hypersensitivity reactions to both oral VRCZ and itraconazole. Because these oral formulations contain no excipient cyclodextrin, the reactions were attributed to the triazole drug substance, consistent with class cross-reactivity. After exhausting alternative antifungal options, VRCZ desensitization was undertaken. An intravenous route was selected as it allows precise dose titration and immediate interruption if required during rapid drug desensitization (RDD), with subsequent transition to oral therapy. The intravenous formulation of VRCZ additionally contains sulfobutyl ether β-cyclodextrin sodium, whose rapid infusion can provoke infusion-related reactions; the prescribing information therefore limits the infusion rate to ≤ 3 mg/kg/h. We modified a previously published RDD protocol to preserve the same cumulative target dose while strictly limiting infusion rate to ≤ 3 mg/kg/h, using only two diluted concentrations and adjusting the infusion rate alone. Desensitization was initiated at 0.05 mg (1/6000 of the planned dose) and escalated through 11 steps at 15-min intervals, with prolongation of the final step to remain within the infusion-rate recommendation. No hypersensitivity reactions occurred during desensitization. The patient subsequently tolerated maintenance intravenous VRCZ, which was switched to the same oral dose. Clinical symptoms improved, and follow-up imaging showed regression of the pulmonary lesion. Distinguishing triazole drug-substance hypersensitivity from excipient-related infusion risk, and controlling the infusion rate accordingly, may improve the safety of intravenous triazole desensitization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.